EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada

Matthew D Seftel iD, Grace Musto, David Allan iD, Oliver Bucher iD, Kevin Hay, Ivan Pasic, Tony Truong, Kristjan Paulson

Current Oncology · 2024

DOI: 10.3390/curroncol32010010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Matthew D Seftel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cells, Canadian Blood Services, Ottawa, ON K1Z 7M3, Canada. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Unrelated Donors. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CTTC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In allogeneic hematopoietic cell transplantation (HCT), a minority of patients have access to a suitable human leukocyte antigen (HLA)-matched related donor (MRD). To fill this gap, matched unrelated donors (MUDs) are an increasingly selected donor source. Usage and outcomes after MUD HCT for Canada are not described. We investigated temporal trends in MUD compared to MRD HCT from 2000 to 2019 using data reported to the Cell Therapy and Transplant Canada (CTTC) Registry. Of 7571 first allogeneic HCTs between 2000 and 2019, the proportion of MUD HCTs rose from 35.1% to 56.3% in the early (2000–2009) and later (2010–2019) eras, respectively. Comparing the two donor sources, the 5-year overall survival (OS) after MUD HCT for patients with malignant diseases was inferior to MRD HCT in the early era (p < 0.001). However, in the later era, OS was comparable for the two donor sources (p = 0.969). For patients with non-malignant diseases, the 5-year OS after MUD HCT was inferior to MRD in the early era (p < 0.001), but in the later era, the 5-year OS was similar between the two donor sources (p = 0.209). Improvements in OS after MUD HCT were accompanied by corresponding reductions in the 2-year non-relapse mortality after MUD HCT. We conclude that MUDs are the most common donor source in Canada, and key clinical outcomes after MUD have improved over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationUnrelated DonorsHumansCanadaMaleFemaleMiddle AgedAdultTreatment OutcomeAdolescentChildAgedYoung AdultChild, Preschool

Stichwörter der Autor:innen

donorshematopoietic cell transplantationreal world evidence

Autor:innen und Institutionen

  • Stem Cells, Canadian Blood Services, Ottawa, ON K1Z 7M3, Canada.
  • Department of Epidemiology, CancerCare Manitoba, Winnipeg, MB R3A 1M5, Canada.
  • Division of Hematology, Department of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
  • Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
  • Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Calgary, Calgary, AB T3B 6A8, Canada.
  • CancerCare Manitoba, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.

ORCID-Profile: Matthew D Seftel, David Allan, Oliver Bucher

Förderung

  • CTTC

Zitieren

APA

Seftel, M. D., Musto, G., Allan, D., Bucher, O., Hay, K., Pasic, I., Truong, T., & Paulson, K. (2024). Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada. Current Oncology. https://doi.org/10.3390/curroncol32010010

Vancouver

Seftel MD, Musto G, Allan D, Bucher O, Hay K, Pasic I, et al. Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada. Current Oncology. 2024. doi:10.3390/curroncol32010010

BibTeX
@article{Seftel2024,
  author = {Seftel, Matthew D and Musto, Grace and Allan, David and Bucher, Oliver and Hay, Kevin and Pasic, Ivan and Truong, Tony and Paulson, Kristjan},
  title = {Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol32010010}
}
Kostenlos starten →